G2GBIO specializes in the development of long-acting microsphere products. We have been developing a unique InnoLAMP technology which can make monodisperse microspheres composed of various polymers for long-acting drugs or dermal fillers.
Our proprietary platform technology enables us to produce microspheres with the exact desired size and a finely controlled drug release profile.
InnoLAMP technology distinguishes itself from other conventional technologies with its simple aseptic process and the ease to scale-up the manufacturing process.
Our technology can be applied to treatment of various medical conditions such as central nervous system diseases, including dementia or schizophrenia, and chronic diseases, such as cancer and diabetes. We will gradually expand our target to a variety of other diseases with unmet needs for sustained release of injection medication.